Patient-reported outcomes of cemiplimab versus chemotherapy in advanced NSCLC: PD-L1 level subgroups in EMPOWER-lung 1
Küçük Resim Yok
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Science
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Patient-reported outcomes of cemiplimab versus chemotherapy in advanced NSCLC: PD-L1 level subgroups in empower-lung 1
Açıklama
Anahtar Kelimeler
Non-Small Cell Lung Cancer, Patient-Reported Outcomes, Cemiplimab
Kaynak
JOURNAL OF THORACIC ONCOLOGY
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
17
Sayı
9
Künye
Kilickap, S., Sezer, A., Gumus, M., Bondarenko, I., Ozguroglu, M., Gogishvili, M., ... & Quek, R. G. (2022). Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1.
